Plasmacytoid and conventional dendritic cells (pDCs and cDCs) arise from monocyte and dendritic progenitors (MDPs) and common dendritic progenitors (CDPs) through gene expression changes that remain partially understood. Here we show that the Ikaros transcription factor is required for DC development at multiple stages. Ikaros cooperates with Notch pathway activation to maintain the homeostasis of MDPs and CDPs. Ikaros then antagonizes TGFβ function to promote pDC differentiation from CDPs. Strikingly, Ikaros-deficient CDPs and pDCs express a cDC-like transcriptional signature that is correlated with TGFβ activation, suggesting that Ikaros is an upstream negative regulator of the TGFβ pathway and a repressor of cDC-lineage genes in pDCs. Almost all of these phenotypes can be rescued by short-term in vitro treatment with γ-secretase inhibitors, which affects both TGFβ-dependent and -independent pathways, but is Notch-independent. We conclude that Ikaros is a crucial differentiation factor in early dendritic progenitors that is required for pDC identity.
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Introduction
Dendritic cells (DCs) are essential modulators of the immune response [1] . They can be broadly divided into conventional DCs (cDC), which are required for antigen presentation, and plasmacytoid DCs (pDC), which secrete high quantities of type-I interferon (IFN-α, -β, -ω) upon certain viral infections [2, 3] . cDCs are further divided into cDC1 (CD8 + ) and cDC2 (CD11b + ) subsets. Both DC lineages develop in the bone marrow. Monocyte and dendritic progenitors (MDPs) are the earliest known DC precursors, and they give rise to monocytes and common dendritic progenitors (CDPs) [4] [5] [6] . In turn, CDPs differentiate into pDCs and pre-cDCs, the latter of which migrate to the periphery to become cDCs. The molecular circuits regulating DC cell fate have been intensively studied, and some transcriptional regulators (Ikaros, E2.2, PU.1, IRF8, GFI1, NFIL3, BATF3, BCL11a) and canonical signaling pathways (TGFβ, Notch, Wnt) have been identified [3, [7] [8] [9] [10] [11] [12] . However, the relationships and interactions between these players remain unclear, and this is important to understand if we wish to manipulate DC function.
Deficiency of the Ikaros zinc finger DNA-binding protein and tumor suppressor, encoded by the Ikzf1 gene, is associated with profoundly impaired DC development. Mice homozygous for a dominant-negative (dn) Ikzf1 mutation lack all cDCs, while animals with a null mutation predominantly lack cDC2s [13] . In contrast, mice carrying the hypomorphic Ik L/L mutation show a selective block in bone marrow (BM) pDC development, leading to an absence of peripheral pDCs, although cDCs appear normal [14] . These studies highlight the sensitivity of the DC lineages to Ikaros levels, where pDC development requires more Ikaros function than cDCs. In man, patients with germline IKZF1 mutations also exhibit reduced pDC, but not cDC numbers, indicating a conserved role for Ikaros in DC development [15] . Interestingly, IKZF1 deletions are associated with blastic plasmacytoid dendritic cell neoplasms (BPDCN), a malignancy of pDC precursors with poor prognosis [16] [17] [18] . Thus Ikaros is required for DC development, but little is known about its molecular mechanisms.
Here we show that Ikaros deficiency leads to multiple defects in pDC and cDC development. In particular, Ikaros is required for CDP development, where it antagonizes TGFβ function to promote pDC differentiation. We further show that Ikaros cooperates with Notch pathway activation to support the homeostasis of DC progenitors. Lastly, we show that a transient incubation of bone marrow cells with γ-secretase inhibitors rescues pDC development from WT and Ikaros-deficient BM progenitors, revealing a potentially novel way to enhance pDC function.
Results

Ikaros is required for CDP differentiation
To determine how pDC differentiation is affected by Ikaros deficiency, we evaluated DC progenitor populations in Ik L/L mice. Ik L/L cells express functional Ikaros proteins at~10% of WT levels, and although Ik L/L mice die from Notch-dependent T cell leukemias at 4-6 months of age, the animals studied (6-8 weeks of age) showed no signs of transformation (normal CD4/CD8 profiles, T cell receptor chain usage, Notch pathway activation) [19] [20] [21] . 
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-pre-cDCs, and splenic cDCs (Fig 1) [ [4] [5] [6] 22] . In the BM, CDP numbers were significantly increased and pDC and pre-cDC numbers were significantly decreased in Ik L/L mice, suggesting that Ik L/L DC differentiation is blocked at the CDP stage ( Fig 1A-1C, 1E and 1F ). In the spleen, Ik L/L animals had no detectable pDCs, as previously reported [13, 14] , fewer cDC2s, but similar numbers of cDC1s compared with WT (Fig 1D and 1G) . Thus Ikaros deficiency results in the specific accumulation of BM CDPs. The Notch pathway is activated in Ikaros-deficient pDCs
We previously observed in a genome-wide study that genes associated with the Notch pathway (eg. Hes1, Ptcra, Uaca) are upregulated in the BM pDCs of Ik L/L mice [14] . Higher Hes1 and Ptcra mRNA levels were confirmed by RT-qPCR (Fig 2A) . (Fig 2D) [24, 25] . CCR9 lo pDCs from WT Hes1-GFP KI mice did not express GFP. These data indicated that the Hes1 locus, and perhaps the Notch pathway, are ectopically activated during pDC development in the mutant mice. (Fig 3A) . Strikingly, GSI treatment significantly enhanced WT pDC differentiation, and rescued pDC development in the Ik L/L cultures to levels of WT cells. This occurred early, as GSI treatment at day 0 was both necessary and sufficient to rescue Ik L/L pDC development (Fig 3B and 3C) . Similar results were obtained with other GSI compounds (DAPT and MRK003). In addition, early GSI treatment resulted in an increase in total cell numbers (Fig 3D) , which correlated with an expansion of immature CD11c -cells, particularly in the Ik L/L cultures (Fig 3B) . The pDCs produced in the GSI-treated cultures were more immature, and expressed low levels of CCR9 and Ly49Q ( Fig 3E) 
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-cells ("CD115 -CDPs") in these assays, as they were reported to contain pDC-specific precursors [28] , even though they existed in similar numbers in WT and Ik L/L BM (S1A and S1B Fig (Fig 4C and 4D ). WT cells generated slightly more pDCs after GSI treatment compared with DMSO. Importantly, the CD45.1 + supporting cells produced similar frequencies of pDCs in all conditions, indicating that GSI treatment enhanced Ik L/L and WT pDC differentiation in a cell-intrinsic manner. Collectively, our results indicated that γ-secretase inhibitors rescue Ikaros-deficient pDC development in vitro and in vivo.
GSI promotes CDP differentiation via Notch-independent pathways
Because γ-secretase inhibitors affect other pathways in addition to Notch, we tested the role of Notch activation in pDC development by genetic means. Ik L/L mice were crossed with animals carrying a floxed null allele for Rbpj (Rbpj f/f ), the Notch transcriptional mediator, and the R26-CreERT2 transgene [29, 30] .
(Ik L/L RBPJ KO) mice, along with control animals, were treated with tamoxifen for 5 days to delete Rbpj, and analyzed 5 days after the last injection. Deletion was confirmed by Western blot ( S3 Fig). BM cells from the tamoxifen-treated mice were cultured with Flt3L for 8 days, in the presence or absence of GSI, and cell expansion and pDC development were studied ( Fig  5A and 5B) . In these experiments, we reasoned that if GSI rescues pDC development by inhibiting Notch signaling, then (i) Rbpj inactivation should mimic the effects of GSI, and (ii) GSI should not have additional effects when Rbpj is deleted.
When cell numbers were evaluated, we observed that the samples treated with GSI contained significantly higher numbers of cells, regardless of RBPJ and/or Ikaros status (Fig 5B) . This suggested that GSI inhibits the function of pathways other than Notch. Likewise, when pDC development was evaluated (Fig 5A and 5B Collectively, our results demonstrate that GSI treatment inhibits a Notch-independent pathway important for CDP development.
The TGFβ pathway is activated in Ikaros-deficient CDPs
To further investigate the molecular pathways targeted by Ikaros and γ-secretase in CDPs, we studied the transcriptome profiles of WT and Ik L/L MDPs and CDPs, cultured in the presence or absence of GSI. We used a protocol similar to the one above, and co-cultured CD45. progenitors and mature DC populations, as reported by the ImmGen Compendium (GSE15907), using unsupervised clustering [7] . Interestingly, this revealed that, among the genes up-regulated in Ik L/L CDPs (Fig 6B) , the large majority (>70%) were related to mature cDC genes, and not pDCs. The remainder of the genes were DC progenitor-related. In contrast, among the genes down-regulated in Ik GSI and DMSO treated samples (Fig 6C, S1 Table) . To identify the potential upstream pathways involved in the regulation of their expression in DC progenitors, we performed Ingenuity Pathway Analysis (Fig 6D) . This revealed Ikaros to be a significant probable regulator, which validated our approach, and showed the importance of Ikaros in CDPs. The top candidate, however, was TGFβ1, which was interesting because TGFβ1 was previously reported to skew CDP differentiation towards the cDC lineage at the expense of pDCs [9] . We therefore asked if the deregulated genes found in Ik L/L CDPs were enriched for TGFβ-associated genes, by GSEA. These results showed a strong and direct correlation between the genes down-regulated in Ik L/L CDPs and those down-regulated by TGFβ1 signaling (Fig 6E) [9] . Conversely, the genes up-regulated in Ik L/L CDPs were up-regulated by TGFβ1 activation (Fig 6F) . Thus, Ikaros expression is correlated with reduced TGFβ1 signaling in CDP cells. To determine if Ikaros directly regulates the TGFβ pathway, we investigated its capacity to bind TGFβ target genes. The low number of CDPs in WT mice did not allow us to directly investigate Ikaros binding in these cells. We therefore compared Ikaros binding to chromatin from 2 unrelated precursor cell types (pre-B cells and DN3 thymocytes) [31, 32] , because conserved binding might indicate that Ikaros regulates similar elements across hematopoietic cell types. These analyses showed strong and conserved Ikaros binding to several TGFβ target genes implicated in DC differentiation (eg. Axl, Irf1, Irf4, Nfkb2, Nfkbie, Rel, Relb) (Fig 6G and  S4 Fig) , and suggested that Ikaros may directly regulate the expression of TGFβ target genes in CDPs.
Inhibition of TGFβ signaling rescues Ikaros-deficient pDC development
To determine if the TGFβ pathway is activated in Ik L/L CDPs, we studied the mRNA expression of genes encoding upstream components of this pathway. Although the level of transcripts encoding the type I and type II TGFβ receptors, and the downstream SMAD proteins, were similar between WT and Ik L/L MDPs and CDPs, we found that the mRNA levels of Eng, encoding the type III TGFβ receptor Endoglin, was higher in Ik L/L MDPs (2x) and CDPs (2.8x), regardless of GSI treatment (Fig 6A) . Endoglin (CD105), is an auxiliary receptor for the TGFβ receptor complex, which has been shown to positively modulate TGFβ signaling [33] . Higher CD105 expression was also detected on Ik L/L MDPs, CDPs and pDCs (Fig 7A and 7B) . (Fig 7C and   7D ). In contrast, GSI treatment alone increased both total cell numbers and pDC numbers. The combination of SB431542 and GSI gave similar total and pDC numbers, compared with GSI alone. These results suggested that TGFβ inhibition promotes pDC differentiation in Ik L/L CDPs.
Discussion
Here we identify Ikaros as a promoter of early DC development. We show that Ikaros cooperates with Notch signaling to enhance the emergence and/or survival of MDPs and CDPs in the BM (Fig 7E) . We also show that Ikaros is required to promote CDP differentiation and cell fate specification towards the pDC and cDC lineages, in large part by correctly regulating the expression of DC-specific target genes, and secondly, by antagonizing TGFβ function. These results indicate that the general absence of mature DCs in Ikaros null mice [13, 34] , as well as the selective absence of pDCs in Ikaros hypomorphic animals [14] , are due at least in part to CDP defects. Our results suggest that Ikaros antagonizes a TGFβ-dependent gene expression program in CDPs. TGFβ was previously reported to skew CDP differentiation towards the cDC lineage at the expense of pDCs, in part because it induces the expression of Id2, which inhibits the master pDC regulator E2.2 [9, [35] [36] [37] . We show that Ikaros-deficient CDPs display a premature cDC gene expression signature, indicating that Ikaros represses the expression of mature cDC-associated genes in DC progenitors. In addition, Ikaros-deficient BM pDCs also display a cDC signature, suggesting that the mutant CDPs that commit to the pDC lineage continue to express a promiscuous cDC gene expression program. Neither Id2 nor E2.2 are affected at the mRNA level in Ikaros-deficient CDPs and pDCs, suggesting that Ikaros promotes CDP differentiation independently of E2.2.
How Ikaros antagonizes TGFβ function remains only partially understood. Certain TGFβ target genes are enriched among the genes deregulated by GSI in CDPs. Furthermore, Ikarosdeficient CDPs ectopically express high levels of endoglin which can potentiate TGFβ signaling [38] . Because no other TGFβ receptors or downstream SMAD factors are deregulated in these cells, endoglin upregulation probably plays an important role in activating the TGFβ pathway in the mutant DC progenitors. Interestingly, betaglycan, a type III TGFβ receptor closely related to endoglin in structure and function, is a substrate of γ-secretase, and GSI inhibits TGFβ2-mediated reporter gene expression via betaglycan inactivation in HepG2 cells [39] . γ-secretase cleavage of type III TGFβ receptors may therefore inhibit TGFβ receptor signaling in Ikaros-deficient cells. If true, this suggests that Ikaros may be a novel upstream regulator of TGFβ signaling.
In addition to its role in CDP differentiation, Ikaros is also required for MDP and CDP homeostasis. Observed only in compound mutants deficient for Ikaros and RBPJ where both populations are absent, our results demonstrate that Ikaros cooperates with Notch activation to maintain DC progenitor survival and/or expansion. Notch signaling by itself was previously found to promote DC development in vitro via up-regulation of the Frizzled family Wnt receptors [10] , but the basis for its cooperation with Ikaros remains to be elucidated. We have reported that Ikaros antagonizes Notch function in T cells, and interacts directly with the activated Notch1 protein to control a set of common target genes [40] . Whether Ikaros and Notch regulate common genes in DC progenitors remains to be investigated. Other studies have suggested that the Notch and TGFβ pathways interact to regulate common genes. Indeed, Hes1 is a common target of both pathways, because it is transcriptionally regulated by the Notch receptor intracellular domain or by Smad3 following TGFβ signaling [41] . In Ik L/L cells, however, Hes1 up-regulation was observed in pDCs but not in the more immature dendritic progenitors, suggesting that Hes1 is differentially regulated by Notch and TGFβ activation in these populations. Finally, our results with γ-secretase inhibitors are unexpected and intriguing, and indicate that these compounds can be exploited to enhance and rescue WT and Ikaros-deficient DC development in vitro, though the effects are stronger in the mutant cells. We showed that transient GSI treatment promotes the generation of CD11c -cells, probably the upstream precursors of MDPs and CDPs, and pDC differentiation from CDPs. These actions suggest that GSI molecules might be considered as a potential treatment to enhance pDC function during certain viral infections, like chronic HIV or hepatitis C virus. Conversely, it will be important to test if GSI molecules might have a differentiating effect on BPDCN cancers, a rare and fatal leukemia with few options for treatment [42] .
Materials and methods
Ethics statement
All mouse procedures were approved by the IGBMC Ethical Committee (Com'Eth); APA-FIS#8752-20 170 1261 0337966 v2.
Mice
The mouse lines used in this study were described previously: Ik
and R26-CreER(T2) [19, 23, 29, 30] . Mice were used between 6-9 weeks of age. To delete Rbpj in vivo, RBPJ f/f R26-CreET(T2) + or Ik L/L RBPJ f/f R26-CreET(T2) + mice were injected intraperitoneally daily for 5 days with 75 mg/kg of tamoxifen dissolved in sunflower oil, and analyzed 10 days after the first injection.
Cell culture
pDC cultures were performed as described [26] . Briefly, BM cells were seeded at 2x10 6 cells/ ml, and cultured in RPMI 1640 containing 10% fetal calf serum, 20 mM HEPES, 2 mM L-glutamine, 2 mM Sodium Pyruvate, 50 μM β-mercaptoethanol, 1x MEM non-essential amino acids, and antibiotics. Cultures were supplemented with conditioned medium from a Flt3L-producing cell line (B16-Flt3L) [43] , or rFlt3L at 100 ng/ml (Peprotech). After 4d, half of the medium was replaced with fresh medium containing 2x Flt3L. GSI (Compound E, Calbiochem) and SB431542 (Selleckchem) were used at 5 μM. pDC cultures from DC progenitors were performed as above in 1 ml of Flt3L-supplemented medium using FACS- 
RT-qPCR
RNA was extracted with the RNeasy (Qiagen) or Nucleospin RNA (Macherey-Nagel) kits, and reverse transcribed using Superscript II (Invitrogen). Hes1, Ptcra and Hprt were amplified using the QuantiTect SYBR green system with the Mm_Hes1_1SG, Mm_PtcrA_1SG and Mm_Hprt_1SG primer sets (Qiagen). Ifna mRNA was amplified using the SYBR green master mix (Roche) with 50 cycles of 10s 95˚C, 30s 66˚C, 15s 72˚C. Primers used to amplify most of the Ifna subtypes were 5'-cctgctggctgtgaggaaata and 5'-gcacagggggctgtgtttct. Primers for Ubiquitin (Ubb) were 5'-tggctattaattattcggtctgcat and 5'-gcaagtggctagagtgcagagtaa. Hes1 and Ptcra levels were normalized to that of Hprt, while Ifna expression was normalized to that of Ubb.
Flow cytometry
We used the following antibodies: anti-CD11b (M1/70) eFluor450 or PE; anti-CD11c (N418) AlexaFluor700; anti-human/mouse CD45R (B220) eFluor650NC; anti-CD59 and Gr1 (RB6-8C5) biotin; anti-CD199 (CCR9) PE/Cy7; anti-CD317 (ebio927) AlexaFluor488 or eFluor450; anti-MHCII (M5/114.15.2) FITC or PE/Cy5; anti-Sca1 (D7) biotin (eBioscience); anti-CD3 (145-2C11) biotin; anti-CD4 (RM4-5) biotin; anti-CD8 (53-6.7) biotin; anti-CD11b (M1/70) biotin; anti-CD45.1 (A20) PE; anti-human/mouse CD45R (B220) biotin; anti-CD115 (c-fms) APC; anti-CD135 (A2F10) PE; anti-CD172a (P84) APC; anti-NK1.1 (PK136) biotin; antiTer119 biotin (BD Biosciences); anti-CD11c (N418) biotin or APC; anti-CD19 (6D5) biotin; anti-CD45.1 (A20) FITC; anti-CD45.2 (104.2) PE or AlexaFluor700; anti-CD105 (Endoglin) Alexa488; anti-CD117 (c-kit) APC/Cy7; anti-Ly49Q (2E6) PE (MBL); anti-SiglecH (551.3D3) PE (BioLegend); AlexaFluor™ 405 (InvitroGen) or AlexaFluor488 Streptavidin (Jackson ImmunoResearch). Lineage staining was performed using a mixture of anti-CD3, -CD4, -CD8, -CD19, -CD11b, -CD11c, -Gr1, -Ter119, -NK1.1 and -B220 antibodies for Lin, and anti-CD3, -CD19, -Ter119, -NK1.1 and -B220 for Lin Ã . Cells were analyzed on a LSRII analyzer (BD Biosciences) and sorted on a FACSAriaIISORP (BD Biosciences). Sort purity was >98%.
Western blotting
Total protein extracts from 10 6 BM cells were separated on SDS-PAGE gels. Immunoblots were analyzed with anti-RPBJ (T6719; Institute of Immunology, Japan), and anti-β-actin (A5441, Sigma) polyclonal antibodies. All secondary antibodies were horseradish conjugated (Santa Cruz, Jackson ImmunoResearch).
Microarray analysis
Transcriptome analyses were performed with Affymetrix Gene ST 1.0 arrays. Unsupervised hierarchical clustering and K-means clustering were performed using Cluster 3. GSEA was performed using the GSEA 2.0 software [44, 45] . Microarray data are available in the GEO databank (GSE114108). 
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